VTYX Q3 2023 Earnings — Ventyx Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

VTYXVentyx Biosciences, Inc.

$1B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$58M

Net Income

-$54M

EPS (Diluted)

$-0.92

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$322M

Total Liabilities

$38M

Stockholders' Equity

$284M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$58M	-$31M	-84.4%
Net Income	-$54M	-$30M	-77.4%